Transcatheter aortic valve replacement (TAVR)
Clinical evidence
The Medtronic CoreValve™/Evolut™ platform is supported by a robust body of clinical evidence. Explore the CoreValve™/Evolut™ clinical success.
Comprehensive clinical evidence
Stay up to date on the latest clinical evidence from Medtronic. Key summaries demonstrate the efficacy of the CoreValve™/Evolut™ TAVR platform.
Real-world results
The CoreValve™/Evolut™ platform provides reproducible results from clinical trial to the real world.
Explore our STS/ACC TVT Registry™* data that supports the excellent clinical performance seen in our trials.
EXPAND TAVR II Pivotal Trial
The purpose of the EXPAND TAVR II Pivotal Trial is to explore the treatment of moderate aortic stenosis (AS) with early aortic valve replacement (AVR) before AS becomes severe. This can lead to preservation of cardiac function, prevention of further deterioration in cardiac function, and prevention of death in some patients.
Connect with us on social.
LinkedIn: Medtronic Cardiac and Vascular
Related products
-
Confida™ Brecker guidewireThe Confida™ Brecker guidewire is specifically designed for transcatheter aortic valve replacement (TAVR) procedures.
-
Evolut™ FX systemThe Evolut™ FX transcatheter aortic valve replacement (TAVR) system sets new expectations for precision, control, and predictability in TAVR procedures.
-
Evolut™ FX+ systemThe Evolut™ FX+ transcatheter aortic valve system is designed with specific features intended to enable lifetime management solutions such as coronary access.
-
Evolut™ PRO+ systemThe Evolut™ PRO+ TAVR system features the lowest delivery profile for 23–29 mm valves and advanced sealing with an external tissue wrap on all valve sizes.